Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

[1]  S. Mulvihill,et al.  Screening for pancreatic cancer. , 2014, Advances in surgery.

[2]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[3]  P. Illei,et al.  O-0004SPARC ANALYSIS IN THE PHASE III MPACT TRIAL OF NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) VS GEM ALONE FOR PATIENTS WITH METASTATIC PANCREATIC CANCER (PC) , 2014 .

[4]  S. Sleijfer,et al.  Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. , 2014, Cancer treatment reviews.

[5]  M. Büchler,et al.  Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Haojie Huang,et al.  Oncogenic K-Ras requires activation for enhanced activity , 2014, Oncogene.

[7]  G. Klöppel,et al.  Frequency of Kras Mutations in Pancreatic Intraductal Neoplasias Associated with Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis : A Meta-Analysis 1 , 2014 .

[8]  John R. Mackey,et al.  Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. , 2014, Journal of the National Cancer Institute.

[9]  V. Heinemann,et al.  Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Gibbs,et al.  Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. , 2013, Gastroenterology.

[11]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[12]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[13]  Wei-Chih Liao,et al.  Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. , 2013, The Lancet. Oncology.

[14]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[15]  N. Sata,et al.  JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. , 2013 .

[16]  Jeffrey W. Clark,et al.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. , 2013, The oncologist.

[17]  D. Goldstein,et al.  Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Rad,et al.  Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. , 2013, Cancer cell.

[19]  J. Tabernero,et al.  Development of PI3K inhibitors: lessons learned from early clinical trials , 2013, Nature Reviews Clinical Oncology.

[20]  N. Sata,et al.  Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). , 2013 .

[21]  S. Mulvihill,et al.  Screening for Pancreatic Cancer: Why, How, and Who? , 2013, Annals of surgery.

[22]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[23]  T. Buchholz.  Bayesian analysis unravels pancreas-cancer adjuvant therapy , 2013 .

[24]  B. Bao,et al.  Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. , 2012, Current drug targets.

[25]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[26]  S. Batra,et al.  Early diagnosis of pancreatic cancer: challenges and new developments. , 2012, Biomarkers in medicine.

[27]  E. Van Cutsem,et al.  Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  M. Barbacid,et al.  EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[29]  Jens T Siveke,et al.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.

[30]  Isabelle Salmon,et al.  Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. , 2012, Gastroenterology.

[31]  I. Salmon,et al.  Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Manuel Hidalgo,et al.  Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas , 2012, Clinical Cancer Research.

[33]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[34]  W. Greenhalf,et al.  New biomarkers and targets in pancreatic cancer and their application to treatment , 2012, Nature Reviews Gastroenterology &Hepatology.

[35]  M. Büchler,et al.  Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. , 2012, JAMA.

[36]  K. Kinzler,et al.  Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity , 2012, Clinical Cancer Research.

[37]  Stefan K. Maier,et al.  MALDI Imaging Mass Spectrometry for In Situ Proteomic Analysis of Preneoplastic Lesions in Pancreatic Cancer , 2012, PloS one.

[38]  S. Barni,et al.  FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study , 2012, Cancer Chemotherapy and Pharmacology.

[39]  J. Wei,et al.  Treatment of pancreatic cancer with bifunctional siRNA silencing TGF-b and activating RIG-I , 2012 .

[40]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[41]  D. Tuveson,et al.  Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma , 2012, The Journal of experimental medicine.

[42]  K. Lim,et al.  Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? , 2012, The oncologist.

[43]  D. Tuveson,et al.  Understanding Metastasis in Pancreatic Cancer: A Call for New Clinical Approaches , 2012, Cell.

[44]  M. Gumus,et al.  Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. , 2012, Neoplasma.

[45]  A. Jah,et al.  Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[46]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Neoptolemos,et al.  Partial Pancreatic Resection for Pancreatic Malignancy Is Associated with Sustained Pancreatic Exocrine Failure and Reduced Quality of Life: A Prospective Study , 2011, Pancreatology.

[48]  C. Tung,et al.  Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models , 2011, Gut.

[49]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Mazur,et al.  Abstract PR11: Egfr is essential for Ras-driven pancreatic cancer development , 2011 .

[51]  B. Agarwal,et al.  Imaging of pancreatic cancer: An overview. , 2011, Journal of gastrointestinal oncology.

[52]  Jeffrey E. Lee,et al.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Temel,et al.  Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[55]  W. Hawkins,et al.  Potential targets for pancreatic cancer immunotherapeutics. , 2011, Immunotherapy.

[56]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[57]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[58]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[59]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[60]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[61]  B. Chauffert,et al.  Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) , 2010, Gut.

[62]  L. Collette,et al.  Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Bing Xia,et al.  PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.

[64]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[65]  J. Tokar,et al.  Defining Venous Involvement in Borderline Resectable Pancreatic Cancer , 2010, Annals of Surgical Oncology.

[66]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[67]  M. Hidalgo,et al.  A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model , 2010, Molecular Cancer Therapeutics.

[68]  R. Labianca,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[70]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Neoptolemos,et al.  Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin , 2009, Histopathology.

[72]  H. Ueno,et al.  A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer , 2009, British Journal of Cancer.

[73]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[75]  N. Girard,et al.  Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[77]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  M. Büchler,et al.  Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials , 2009, British Journal of Cancer.

[79]  Adam P Dicker,et al.  Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. , 2009, Gastroenterology.

[80]  F. Brunetti,et al.  Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. , 2008, Critical reviews in oncology/hematology.

[81]  Helmut Friess,et al.  The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[82]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[83]  D. Simeone.  Pancreatic Cancer Stem Cells: Implications for the Treatment of Pancreatic Cancer , 2008, Clinical Cancer Research.

[84]  Steven Gallinger,et al.  Germline BRCA1 mutations predispose to pancreatic adenocarcinoma , 2008, Human Genetics.

[85]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  F. Real,et al.  Pancreatic cancer development and progression: remodeling the model. , 2008, Gastroenterology.

[87]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  B. Dörken,et al.  A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study , 2008 .

[89]  H. Friess,et al.  Most Pancreatic Cancer Resections are R1 Resections , 2008, Annals of Surgical Oncology.

[90]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[91]  Kathleen M. Egan,et al.  Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis , 2008, Familial Cancer.

[92]  R. Labianca,et al.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.

[93]  D. Ankerst,et al.  The Role of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer: Systematic Review of Randomized Controlled Trials and Meta-Analysis , 2008, Oncology.

[94]  R. Hruban,et al.  Precursors to pancreatic cancer. , 2007, Gastroenterology clinics of North America.

[95]  P. Hwu,et al.  Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. , 2007, Vaccine.

[96]  Murray Korc,et al.  Pancreatic cancer-associated stroma production. , 2007, American journal of surgery.

[97]  Helmut Friess,et al.  Pancreatic cancer microenvironment , 2007, International journal of cancer.

[98]  Catrin Tudur Smith,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[102]  A. Maitra,et al.  Genetics and pathology of pancreatic cancer. , 2006, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[103]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  M. Löhr.  Is it possible to survive pancreatic cancer? , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[105]  T. Kosuge,et al.  A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. , 2006, Japanese journal of clinical oncology.

[106]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[107]  H. Friess,et al.  Osteonectin Influences Growth and Invasion of Pancreatic Cancer Cells , 2005, Annals of surgery.

[108]  S. Majumdar,et al.  Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma , 2005, BMC gastroenterology.

[109]  F. di Costanzo,et al.  Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC) , 2005, British Journal of Cancer.

[110]  M. Stauch,et al.  A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer , 2005 .

[111]  W. Scheithauer,et al.  Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) , 2005 .

[112]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  A. Buck,et al.  Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. , 2005, Gastroenterology.

[114]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[115]  A. Harris,et al.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.

[116]  T. Takada,et al.  Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer , 2004, British Journal of Cancer.

[117]  M. Löhr,et al.  Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. , 2005, Neoplasia.

[118]  M. Ychou,et al.  Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[120]  D. Gouma,et al.  Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. , 2004, European journal of cancer.

[121]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[122]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[123]  F. Real.  A "catastrophic hypothesis" for pancreas cancer progression. , 2003, Gastroenterology.

[124]  D. Lorenz,et al.  Long-term Results of Partial Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreatic Head: 25-Year Experience , 2003, World Journal of Surgery.

[125]  W. Scheithauer,et al.  Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[126]  T. Takada,et al.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? , 2002, Cancer.

[127]  L. Buscail,et al.  [Molecular pathways of pancreatic carcinogenesis]. , 2002, Annales de pathologie.

[128]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  G. Colucci,et al.  Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma , 2002, Cancer.

[130]  D. Kerr,et al.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial , 2001, The Lancet.

[131]  J. Ringel,et al.  Transforming Growth Factor-β1 Induces Desmoplasia in an Experimental Model of Human Pancreatic Carcinoma , 2001 .

[132]  J. Jeekel,et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.

[133]  G. Tytgat,et al.  Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region , 1998, Gut.

[134]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[135]  Y. Shiratori,et al.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. , 1996, Gastroenterology.

[136]  S. Hirohashi,et al.  Pancreatic adenocarcinomas frequently show p53 gene mutations. , 1993, The American journal of pathology.

[137]  M. Kalser,et al.  Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer , 1987, Cancer.

[138]  S. Ellenberg,et al.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.

[139]  M M Grajower,et al.  Familial pancreatic cancer. , 1983, Annals of internal medicine.